Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Oncopeptides AB's Enterprise Value is kr555.65 Mil.
Oncopeptides AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was kr-202.35 Mil. Therefore, Oncopeptides AB's EV-to-EBIT ratio for today is -2.75.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Oncopeptides AB's Enterprise Value is kr555.65 Mil.
Oncopeptides AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr-202.35 Mil. Therefore, Oncopeptides AB's EV-to-EBITDA ratio for today is -2.75.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Oncopeptides AB's Enterprise Value is kr555.65 Mil.
Oncopeptides AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was kr83.35 Mil. Therefore, Oncopeptides AB's EV-to-Revenue ratio for today is 6.67.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Oncopeptides AB's Enterprise Value is kr555.65 Mil.
Oncopeptides AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr-193.77 Mil. Therefore, Oncopeptides AB's EV-to-FCF ratio for today is -2.87.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Oncopeptides AB (LTS:0RN4) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Oncopeptides AB's current Enterprise Value is kr555.65 Mil.
Oncopeptides AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-202.35 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Oncopeptides AB's current Enterprise Value is kr555.65 Mil.
Oncopeptides AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-202.35 Mil.
Oncopeptides AB's current Enterprise Value is kr555.65 Mil.
Oncopeptides AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr83.35 Mil.
Oncopeptides AB's current Enterprise Value is kr555.65 Mil.
Oncopeptides AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-193.77 Mil.
Oncopeptides AB's current Enterprise Value is kr555.65 Mil.
Oncopeptides AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-193.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncopeptides AB Enterprise Value Related Terms
Oncopeptides AB Enterprise Value Historical Data
* Premium members only.
The historical data trend for Oncopeptides AB's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RN4 vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Oncopeptides AB's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Oncopeptides AB's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of kr555.65 Mil mean?
Oncopeptides AB (LTS:0RN4) has a Enterprise Value of kr555.65 Mil as of Jul. 07, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Oncopeptides AB and its competitors.
Is Oncopeptides AB's Enterprise Value too high?
Oncopeptides AB's current Enterprise Value is kr555.65 Mil. Overall, Oncopeptides AB has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's Enterprise Value compare to VRTX and REGN?
Oncopeptides AB's Enterprise Value of kr555.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current Enterprise Value is kr555.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (LTS:0RN4) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.23, compared to a current price of kr1.66 — trading 60.8% below its estimated fair value. The current Enterprise Value is kr555.65 Mil. Oncopeptides AB's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Oncopeptides AB (LTS:0RN4), the current Enterprise Value is kr555.65 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (LTS:0RN4) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of kr1.66 is trading 60.8% below its estimated GF Value™ of kr4.23.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for LTS:0RN4:
Enterprise Value: kr555.65 Mil
GF Value™: kr4.23 vs. price of kr1.66 (60.8% below fair value)
No single metric tells the full story. See the LTS:0RN4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
46GF Score
Get the complete analysis for LTS:0RN4
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RN4 has been successfully added to your 
